Investigational drug · Phase 3
OSE2101
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Patients With Non-Small Cell Lung Cancer, Solid Advanced Tumor, Lymphoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
6
Any phase or sponsor naming "OSE2101"
First trial start
2022
Dec 20, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "OSE2101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Patients With Non-Small Cell Lung Cancer
- Solid Advanced Tumor
- Lymphoma
- NSCLC (Non-small Cell Lung Cancer)
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "OSE2101" as an intervention, largest first.
- Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint InhibitorPivotal-lookingRecruiting
OSE ImmunotherapeuticsIndustry
NCT06472245 · 363 participants (planned) · Start Dec 3, 2024 · Primary completion May 1, 2028
Drug: OSE2101; Docetaxel · For: Patients With Non-Small Cell Lung Cancer
Sites: Beverly Hills, California; Encino, California; Los Angeles, California · 207 sites in all
- OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor FailurePivotal-lookingTerminated
OSE ImmunotherapeuticsIndustry
NCT02654587 · 219 participants · Start Feb 12, 2016 · Primary completion Jan 15, 2021
Drug: OSE2101; Docetaxel and 1 more · For: Non Small Cell Lung Cancer
Sites: Burbank, California; Washington D.C., District of Columbia; Boca Raton, Florida · 78 sites in all
- OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OCPivotal-lookingCompleted
ARCAGY/ GINECO GROUPAcademic, hospital or other
NCT04713514 · 185 participants · Start Aug 5, 2021 · Primary completion Dec 15, 2025
Drug: OSE2101; Pembrolizumab 25 MG/ML [Keytruda] · For: Platinum-sensitive Ovarian Cancer; Relapsed Ovarian Cancer
Sites: Leuven, Belgium; Libramont, Belgium; Liège, Belgium · 41 sites in all
- A Randomized Phase II Trial of Cemiplimab Plus OSE2101 ( TEDOPI®) as Maintenance Therapy in ctDNA Positive NSCL. The Cemited Study.Pivotal-lookingRecruiting
Fondazione Ricerca TraslazionaleAcademic, hospital or other
NCT07264673 · 160 participants (planned) · Start Apr 17, 2025 · Primary completion Oct 2027
Drug: Tedopi; Cemiplimab · For: NSCLC
Sites: Roma, Italy
- OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDACPivotal-lookingActive, not recruiting
GERCOR - Multidisciplinary Oncology Cooperative GroupAcademic, hospital or other
NCT03806309 · 106 participants (planned) · Start Apr 10, 2021 · Primary completion Dec 9, 2024
Drug: FOLFIRI; OSE2101 · For: Pancreatic Ductal Adenocarcinoma; Locally Advanced Cancer; Metastatic Cancer
Sites: Amiens, France; Beauvais, France; Besançon, France · 28 sites in all
- Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or LymphomasRecruiting
OSE ImmunotherapeuticsIndustry
NCT05751798 · 41 participants (planned) · Start Dec 20, 2022 · Primary completion Dec 2029
Drug: Part A: OSE-279 100mg; Part A: OSE-279 300mg and 5 more · For: Solid Advanced Tumor; Lymphoma; NSCLC (Non-small Cell Lung Cancer)
Sites: Anderlecht, Belgium; Edegem, Belgium; Lyon, France · 11 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics, and pharmacodynamics of OSE-279, an anti-PD-1 monoclonal antibody in patients with advanced solid tumours.
Robert M, Kotecki N, Gomez-Roca C, et al. · Eur J Cancer 2026
- ARTEMIA phase 3 study: A randomized, open-label trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic non-small cell lung cancer and secondary resistance to immune checkpoint inhibitors.
Liu SV, Dziadziuszko R, Viteri S, et al. · Lung Cancer 2025
- Therapeutic vaccines for advanced non-small cell lung cancer.
Cortés-Jofré M, Rueda-Etxebarria M, Orillard E, et al. · Cochrane Database Syst Rev 2024
- TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.
Kabirian R, Tredan O, Marmé F, et al. · Future Oncol 2024
- Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1.
Besse B, Felip E, Garcia Campelo R, et al. · Ann Oncol 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.